Elicio (ELTX): Price to Sales

Symbol and logo of brand Elicio Therapeutics Inc. (ELTX)

Elicio Therapeutics (ELTX) is managed by experienced immuno-oncology experts, although its pre-revenue stage creates certain risks. Business success relies on the efficacy of new vaccines and patent protection. On GURU.Markets, the company's smoothed P/S ratio demonstrates the influence of these factors, where 86.20 describes the current status of the metric. Project development is supported by seamless interaction with contract research organizations under strict intellectual property control.

ELTX (Elicio) Price-to-Revenue Ratio history from 02/21/2024 to 03/21/2024

Analytical breakdowns for Elicio Therapeutics Inc. (ELTX)

- share price and consensus valuation forecast:
Price Performance Chart Elicio Therapeutics Inc.|ELTX - Price Target Chart
- stock exchange capitalization data:
Market Value Elicio Therapeutics|ELTX - Total Company Value
- shareholders' equity book value data:
Equity per Share Elicio Therapeutics|ELTX - Company Book Value|Market-to-Book Ratio elicio.com|ELTX - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Elicio Therapeutics|ELTX - Long-Term Debt to Capital|Current Liabilities to Capital elicio.com|ELTX - Company Debts|Debts to Net Assets Elicio Therapeutics, Inc|ELTX - Company Long-Term Debts|Short-Term Debt Elicio Therapeutics|Quick Liquidity elicio.com
- net income and valuation multiples indicators:
ELTX - Net Profit|Company Profit Forecast Elicio Therapeutics|ELTX - P/E Multiple|Projected Price to Earnings Elicio|ELTX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Elicio Therapeutics|ELTX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Elicio Therapeutics|ELTX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months elicio.com|ELTX - Net earnings per share growth this year|Projected earnings per share increase next year Elicio Therapeutics
- total revenue and sales volume data:
ELTX - Revenue and Sales Volume|Company Future Revenue Elicio Therapeutics, Inc.|ELTX - P/S Multiple|Market Cap to Future Revenue Ratio Elicio Therapeutics|ELTX - Sales Growth YoY (Last Twelve Months)
Fundamental company analysis:ELTX, Elicio Therapeutics, Inc.
Manufactured products of Elicio Therapeutics, Inc.

Institutional capital evaluates Elicio Therapeutics (ELTX) through the lens of potential capitalization from future monopoly sales of unique antigens with minimal synthesis costs. By analyzing the company's P/S ratio, investors compare the business's market value with actual revenue, allowing them to filter out speculative noise and determine the asset's fair price relative to industry standards.

Competing companies

CRVS (Corvus Pharma) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Prelude Therapeutics Incorporated PRLD